44 patents
Page 2 of 3
Utility
Use of Cannabinoids In the Treatment of a Neurodegenerative Disease or Disorder
18 Mar 21
The present invention relates to the use of cannabinoids in the treatment of a neurodegenerative disease or disorder.
Benjamin Whalley, William Hind, Royston Gray, Javier Fernandez-Ruiz, Eva De Lago, Carmen Rodriguez-Cueto, Laura Garcia-Toscano, Irene Santos-Garcia
Filed: 10 Jul 18
Utility
Cannabinoids In Combination with Non-cannabinoid Chemotherapeutic Agents
11 Mar 21
The invention relates to the use of one or more cannabinoids, particularly THC and/or CBD in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer.
Guillermo VELASCO DIEZ, Manuel GUZMAN PASTOR, Mar LORENTE, Sofia TORRES
Filed: 23 Nov 20
Utility
Use of Cannabinoids In the Treatment of Mental Disorders
4 Mar 21
This invention relates to the use of CBD to treat mental disorders.
Philip ROBSON, Geoffrey Guy, Stephen Wright, Emma Cheetham, Dominic Schiller
Filed: 10 Apr 20
Utility
Modified Release Composition Comprising a Cannabinoid
4 Mar 21
The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, or pharmaceutical composition, comprising a pharmaceutical formulation based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System.
Jitinder WILKHU, Johan BENDER, Mathew COLLINS
Filed: 2 Jan 19
Utility
Pharmaceutical Composition Comprising a Cannabinoid
4 Mar 21
The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System.
Jitinder WILKHU, Johan BENDER
Filed: 2 Jan 19
Utility
Oral Pharmaceutical Formulation Comprising Cannabinoids and Poloxamer
4 Mar 21
The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System.
Jitinder WILKHU, Johan BENDER
Filed: 2 Jan 19
Utility
Cannabidiol Preparations and Its Uses
25 Feb 21
Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol.
Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS, James BRODLE, Katarzyna LACH-FALCONE, Alan SUTTON, Royston GRAY, Rohini Rajyalaxmi RANA
Filed: 26 Apr 19
Utility
Cannabidiol Preparations and Its Uses
21 Jan 21
Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol.
Geoffrey GUY, Volker Knappertz, Benjamin Whalley, Marie Woolley-Roberts, James Brodie, Katarzyna Lach-Falcone, Alan Sutton, Royston Gray, Rohini Rajyalaxmi Rana
Filed: 3 Sep 20
Utility
Use of Cannabinoids In the Treatment of Epilepsy
25 Nov 20
The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE).
Geoffrey GUY, Stephen WRIGHT, Orrin DEVINSKY
Filed: 9 Aug 20
Utility
Use of Cannabinoids In the Treatment of Epilepsy
11 Nov 20
The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking one or more antiepileptic drugs that works via GABA receptor agonism.
Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY
Filed: 21 Jan 19
Utility
Use of Cannabinoids In the Treatment of Epilepsy
14 Oct 20
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures.
Geoffrey GUY, Stephen WRIGHT, Orrin DEVINSKY
Filed: 24 Jun 20
Utility
Extraction of Pharmaceutically Active Components from Plant Materials
30 Sep 20
The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament.
Brian Anthony Whittle, Colin A. Hill, Ian R. Flockhart, David Victor Downs, Peter Gibson, Gary William Wheatley
Filed: 29 Oct 19
Utility
Use of Cannabinoids In the Treatment of Epilepsy
23 Sep 20
The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures.
Geoffrey GUY, Stephen Wright, Orrin Devinsky
Filed: 3 Jun 20
Utility
Use of Cannabidiol In Combination with 5-HT2B Receptor Agonists or Amphetamins In the Treatment of Epilepsy
29 Jul 20
The present invention relates to the use of cannabidiol (CBD) in combination with an agonist of 5-HT2B receptors.
Benjamin WHALLEY, Geoffrey GUY, Volker KNAPPERTZ, Royston GRAY, Rohini RANA
Filed: 30 Sep 18
Utility
Compositions Comprising Cannabinoids for Treatment of Nausea, Vomiting, Emesis, Motion Sickness or Like Conditions
1 Jul 20
Cannabinoids, in particular CBD and CBDA and their acid derivatives are provided for use as an active pharmaceutical substance in the treatment of nausea, vomiting, emesis, motion sickness.
BRIAN ANTHONY WHITTLE, Farideh Afshin Javid
Filed: 5 Aug 19
Utility
7-OH-CANNABIDIOL (7-OH-CBD) And/or 7-OH-CANNABIDIVARIN (7-OH-CBDV) for Use In the Treatment of Epilepsy
1 Jul 20
The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and/or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy.
Colin Stott, Nick Jones, Benjamin Whalley, Gary Stephens, Claire Williams
Filed: 2 Oct 19
Utility
Pharmaceutical Compositions for the Treatment of Disease And/or Symptoms In Arthritis
1 Jul 20
The invention relates to the use of a combination of cannabinoids for the treatment of pain, inflammation and/or disease modification in arthritis.
PHILIP ROBSON, Geoffrey Guy
Filed: 5 Sep 19
Utility
Use of Cannabidiol In the Treatment of Tuberous Sclerosis Complex
1 Jul 20
The present invention relates to the use of cannabidiol (CBD) for the treatment of tumours associated with Tuberous Sclerosis Complex (TSC).
Benjamin WHALLEY, William HIND, Royston GRAY, Michael BAZELOT, Ines De SILVA SERRA, Claire WILLIAMS, Andrew TEE
Filed: 20 Jun 18
Utility
Use of Cannabinoids In the Treatment of Epilepsy
10 Jun 20
The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE).
Geoffrey GUY, Stephen WRIGHT, Alice MEAD, Orrin DEVINSKY
Filed: 13 Feb 20
Utility
Anti-tumoural Effects of Cannabinoid Combinations
6 May 20
The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer.
Guillermo VELASCO DIEZ, Manuel GUZMAN PASTOR, Mar LORENTE, Sofia TORRES, Fatima RODRIGUEZ
Filed: 6 Jun 19